Suppr超能文献

在学术医学中心使用 CliniMACS Prodigy 设备进行封闭式制造 CD19 和双靶点 CD20/19 嵌合抗原受体 T 细胞。

Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.

机构信息

Medical College of Wisconsin, Department of Medicine, Hematology & Oncology Division, Milwaukee, Wisconsin, USA.

Lentigen Technology, Inc., A Miltenyi Biotec Company, Gaithersburg, Maryland, USA.

出版信息

Cytotherapy. 2018 Mar;20(3):394-406. doi: 10.1016/j.jcyt.2017.09.005. Epub 2017 Dec 26.

Abstract

BACKGROUND AIMS

Multiple steps are required to produce chimeric antigen receptor (CAR)-T cells, involving subset enrichment or depletion, activation, gene transduction and expansion. Open processing steps that increase risk of contamination and production failure are required. This complex process requires skilled personnel and costly clean-room facilities and infrastructure. Simplified, reproducible CAR-T-cell manufacturing with reduced labor intensity within a closed-system is highly desirable for increased availability for patients.

METHODS

The CliniMACS Prodigy with TCT process software and the TS520 tubing set that allows closed-system processing for cell enrichment, transduction, washing and expansion was used. We used MACS-CD4 and CD8-MicroBeads for enrichment, TransAct CD3/CD28 reagent for activation, lentiviral CD8 TM-41BB-CD3 ζ-cfrag vectors expressing scFv for CD19 or CD20/CD19 antigens for transduction, TexMACS medium-3%-HS-IL2 for culture and phosphate-buffered saline/ethylenediaminetetraacetic acid buffer for washing. Processing time was 13 days.

RESULTS

Enrichment (N = 7) resulted in CD4/CD8 purity of 98 ± 4.0%, 55 ± 6% recovery and CD3 T-cell purity of 89 ± 10%. Vectors at multiplicity of infection 5-10 resulted in transduction averaging 37%. An average 30-fold expansion of 10 CD4/CD8-enriched cells resulted in sufficient transduced T cells for clinical use. CAR-T cells were 82-100% CD3 with a mix of CD4 and CD8 cells that primarily expressed an effector-memory or central-memory phenotype. Functional testing demonstrated recognition of B-cells and for the CAR-20/19 T cells, CD19 and CD20 single transfectants were recognized in cytotoxic T lymphocyte and interferon-γ production assays.

DISCUSSION

The CliniMACS Prodigy device, tubing set TS520 and TCT software allow CAR-T cells to be manufactured in a closed system at the treatment site without need for clean-room facilities and related infrastructure.

摘要

背景目的

制备嵌合抗原受体(CAR)-T 细胞需要多个步骤,包括亚群富集或耗尽、激活、基因转导和扩增。需要开放的处理步骤来增加污染和生产失败的风险。这个复杂的过程需要熟练的人员和昂贵的洁净室设施和基础设施。简化、可重复的 CAR-T 细胞生产,减少劳动力强度,并在封闭系统中进行,对于增加患者的可用性非常理想。

方法

使用 CliniMACS Prodigy 与 TCT 过程软件和允许进行细胞富集、转导、洗涤和扩增的封闭系统处理的 TS520 管组。我们使用 MACS-CD4 和 CD8-MicroBeads 进行富集,TransAct CD3/CD28 试剂进行激活,慢病毒 CD8 TM-41BB-CD3 ζ-cfrag 载体表达 scFv 用于 CD19 或 CD20/CD19 抗原进行转导,TexMACS 培养基-3%-HS-IL2 用于培养和磷酸盐缓冲盐水/乙二胺四乙酸缓冲液用于洗涤。处理时间为 13 天。

结果

(N=7)的富集结果导致 CD4/CD8 纯度为 98±4.0%,回收率为 55±6%,CD3 T 细胞纯度为 89±10%。感染复数为 5-10 的载体导致平均 37%的转导。10 个 CD4/CD8 富集细胞的平均 30 倍扩增导致足够的转导 T 细胞用于临床使用。CAR-T 细胞为 82-100% CD3,混合有 CD4 和 CD8 细胞,主要表达效应记忆或中央记忆表型。功能测试表明,CAR-20/19 T 细胞能够识别 B 细胞,并且在细胞毒性 T 淋巴细胞和干扰素-γ产生测定中,能够识别 CAR-20/19 T 细胞的 CD19 和 CD20 单一转染体。

讨论

CliniMACS Prodigy 设备、TS520 管组和 TCT 软件允许在治疗现场的封闭系统中制造 CAR-T 细胞,而无需洁净室设施和相关基础设施。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验